Abbott breached ABPI Code after Hidrasec ads appeared on Facebook (public promotion of POM)

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2576/2/13
ComplainantAnonymous, non-contactable general practitioner
CompanyAbbott Healthcare Products Limited
ProductHidrasec (racecadotril)
Main issueHidrasec advertisements visible on Facebook (open access), effectively promoting a POM to the public
Other issues consideredMode of action video caption online; absence of inverted black triangle; paediatric claim wording
Applicable Code year2012
Complaint received6 February 2013
Case completed17 April 2013
AppealNo appeal
Breach clausesClause 9.1; Clause 22.1; Clause 22.2
No breach clausesClause 2; Clause 3.2; Clause 4.11; Clause 7.2
SanctionsUndertaking received; Additional sanctions not stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous GP found Hidrasec (racecadotril) advertisements visible on Facebook and complained that the public could see promotion for a prescription-only medicine (POM).
  • The Facebook content appeared on a UK-based photographer’s portfolio page; Abbott global had supplied campaign images for portfolio use.
  • The Panel questioned whether Abbott global realised the supplied files included promotional text and whether it had checked how/where the material would be used.
  • A separate “Hidrasec Mode of Action” video was found on an animator’s professional website; the only product reference was in the caption beneath the video.
  • The complainant also alleged (a) absence of an inverted black triangle on ads and (b) an inappropriate paediatric claim (“provides rapid control for even your smallest patients”).
  • Abbott said it became aware of the Facebook issue on 8 November 2012, asked its agency to remove the images, investigated, and retrained relevant UK and global staff.
⚖️

Outcome

  • Breach: Facebook placement of Hidrasec advertisements was ruled to be promotion of a POM to the public and to encourage the public to ask a health professional to prescribe it.
  • No breach: The “mode of action” video complaint (Panel could not verify content; only caption referenced Hidrasec; video removed).
  • No breach: Absence of inverted black triangle (complaint not proven on balance of probabilities; MHRA pre-vetting did not request it; product added to list later; Abbott acted quickly once aware).
  • No breach: Claim “provides rapid control for even your smallest patients” (considered within context “licensed in infants older than 3 months” and consistent with SPC; not misleading).
  • No breach: Clause 2 (Panel said Clause 2 is reserved for particular censure and did not apply here).
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training